Xoma Corp said filed registration statement Securities Exchange Commission covering proposed public offering 1.3 mln common share .
Xoma , biotechnology company produce monoclonal antibody-based product treat form cancer , said proceeds used fund research product development , human clinical trial expansion manufacturing capacity working capital .
It said Dillon Read Co Inc Alex Brown Sons Inc manage underwriting .
Reuter & # 3 ; 